Genomic variation-guided management in chronic hepatitis C

Expert Review of Gastroenterology and Hepatology

Volumn 6, Issue 4, 2012, Pages 497-506

  Hsu, Ching Sheng ^a,b   Kao, Jia Horng ^c  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

hepatitis C virus; IL28B SNP; individualized therapy; metabolic profiles; pegylated interferon; viral kinetics

Indexed keywords

ALPHA INTERFERON; BOCEPREVIR; INTERLEUKIN 28; INTERLEUKIN 29; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEGINTERFERON; PEGINTERFERON LAMBDA; PLACEBO; RIBAVIRIN; TELAPREVIR; VANIPREVIR;

AMINO ACID SUBSTITUTION; ANTIVIRAL THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; GENE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; IL28B GENE; ITPA GENE; LIVER FIBROSIS; LIVER TRANSPLANTATION; MISSENSE MUTATION; NATURAL KILLER CELL; NONHUMAN; REVIEW; SEROCONVERSION; SINGLE NUCLEOTIDE POLYMORPHISM; UNSPECIFIED SIDE EFFECT; VIRAL CLEARANCE;

ANTIVIRAL AGENTS; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INDIVIDUALIZED MEDICINE; INTERFERON-ALPHA; INTERLEUKINS; PHARMACOGENETICS; POLYETHYLENE GLYCOLS; PYROPHOSPHATASES; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84865708127     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/egh.12.24     Document Type: Review

References (101)

1. Kao JH, Chen DS. Transmission of hepatitis C virus in Asia: past and present perspectives. J. Gastroenterol. Hepatol. 15(Suppl.), E91-E96 (2000).
2. Chen DS. Hepatitis C virus in chronic liver disease and hepatocellular carcinoma in Taiwan. Int. Symp. Princess Takamatsu Cancer Res. Fund 25, 27-32 (1995).
3. Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 39(4), 1147-1171 (2004).
4. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 36(5 Suppl. 1), S237-S244 (2002). (Pubitemid 35253486)
5. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358(9286), 958-965 (2001). (Pubitemid 32913521)
6. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347(13), 975-982 (2002).
7. Hadziyannis SJ, Sette H Jr, Morgan TR et al.; PEGASYS International Study Group. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140(5), 346-355 (2004).
8. Hsu CS, Liu CH, Liu CJ et al. Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. Antivir. Ther. (Lond.) 14(1), 45-54 (2009).
9. Fan X, Mao Q, Zhou D et al. High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy. Hepatology 50(6), 1765-1772 (2009).
10. Akuta N, Suzuki F, Kawamura Y et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J. Hepatol. 46(3), 403-410 (2007). (Pubitemid 46185701)
11. Hsu SJ, Hsu CS, Liu CH et al. HCV core gene polymorphisms correlate with liver fibrosis but not sustained virological response in patients with genotype 1 infection. Antivir. Ther. (Lond.) 16(2), 227-235 (2011).
12. Chayama K, Tsubota A, Kobayashi M et al. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection. Hepatology 25(3), 745-749 (1997). (Pubitemid 27106464)
13. Yang SS, Lai MY, Chen DS, Chen GH, Kao JH. Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin. Liver Int. 23(6), 426-433 (2003).
14. Hamano K, Sakamoto N, Enomoto N et al. Mutations in the NS5B region of the hepatitis C virus genome correlate with clinical outcomes of interferon-α plus ribavirin combination therapy. J. Gastroenterol. Hepatol. 20(9), 1401-1409 (2005). (Pubitemid 43960839)
15. Lee SD, Yu ML, Cheng PN et al. Comparison of a 6-month course peginterferon α-2b plus ribavirin and interferon α-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. J. Viral Hepat. 12(3), 283-291 (2005).
16. Reddy KR, Hoofnagle JH, Tong MJ et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 30(3), 787-793 (1999). (Pubitemid 29409425)
17. Berg T, Sarrazin C, Herrmann E et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 37(3), 600-609 (2003). (Pubitemid 36258782)
18. Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 46(1), 37-47 (2007). (Pubitemid 47171919)
19. Hsu CS, Liu CH, Liu CJ et al. Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection. Am. J. Gastroenterol. 104(3), 598-604 (2009).
20. Ramcharran D, Wahed AS, Conjeevaram HS et al.; Virahep-C Study Group. Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology 52(3), 854-863 (2010).
21. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 38(3), 639-644 (2003). (Pubitemid 37052150)
22. Persico M, Capasso M, Persico E et al. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: insulin resistance and response to antiviral therapy. Hepatology 46(4), 1009-1015 (2007). (Pubitemid 350144765)
23. Hsu CS, Liu CJ, Liu CH et al. High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. Liver Int. 28(2), 271-277 (2008).
24. Heathcote EJ, Shiffman ML, Cooksley WG et al. Peginterferon α-2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med. 343(23), 1673-1680 (2000).
25. Myers RP, Patel K, Pianko S, Poynard T, McHutchison JG. The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C. J. Viral Hepat. 10(1), 16-22 (2003). (Pubitemid 36237807)
26. Akuta N, Suzuki F, Suzuki Y et al. Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: virological features of IFN-resistant cases with hepatocyte steatosis. J. Med. Virol. 75(4), 550-558 (2005). (Pubitemid 40293522)
27. Patton HM, Patel K, Behling C et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J. Hepatol. 40(3), 484-490 (2004). (Pubitemid 38230851)
28. Lin R, Liddle C, Byth K, Farrell GC. Virus and host factors are both important determinants of response to interferon treatment among patients with chronic hepatitis C. J. Viral Hepat. 3(2), 85-96 (1996). (Pubitemid 126734189)
29. Dill MT, Duong FH, Vogt JE et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 140(3), 1021-1031 (2011).
30. Urban TJ, Thompson AJ, Bradrick SS et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 52(6), 1888-1896 (2010).
31. Honda M, Sakai A, Yamashita T et al.; Hokuriku Liver Study Group. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 139(2), 499-509 (2010).
32. Bitetto D, Fattovich G, Fabris C et al. Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology 53(4), 1118-1126 (2011).
33. Fried MW, Hadziyannis SJ, Shiffman M, Messinger D, Zeuzem S. Rapid viral response is a more important predictor of sustained virological response (SVR) than genotype in patients with chronic hepatitis c virus infection. J. Hepatol., 48(Suppl. 2), 5A (2008).
34. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002-June 10-12, 2002. Hepatology, 36(5 Suppl.1), S3-S20 (2002).
35. Morgan TR, Lambrecht RW, Bonkovsky HL et al.; HALT-C Trial Group. DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J. Hepatol. 49(4), 548-556 (2008).
36. Welzel TM, Morgan TR, Bonkovsky HL et al.; HALT-C Trial Group. Variants in interferon-α pathway genes and response to pegylated interferon-α2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 49(6), 1847-1858 (2009).
37. Yee LJ, Tang J, Gibson AW, Kimberly R, Van Leeuwen DJ, Kaslow RA. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 33(3), 708-712 (2001). (Pubitemid 32185234)
38. Clark PJ, Thompson AJ, McHutchison JG. IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies. Am. J. Gastroenterol. 106(1), 38-45 (2011).
39. Thomas DL, Thio CL, Martin MP et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461(7265), 798-801 (2009).
40. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262), 399-401 (2009).
41. Suppiah V, Moldovan M, Ahlenstiel G et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat. Genet. 41(10), 1100-1104 (2009).
42. Tanaka Y, Nishida N, Sugiyama M et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41(10), 1105-1109 (2009).
43. O'Brien TR. Interferon-α, interferon-λ and hepatitis C. Nat. Genet. 41(10), 1048-1050 (2009).
44. Hsu CS, Hsu SJ, Chen HC et al. Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. Proc. Natl Acad. Sci. USA 108(9), 3719-3724 (2011).
45. Fellay J, Thompson AJ, Ge D et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 464(7287), 405-408 (2010).
46. Ochi H, Maekawa T, Abe H et al. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy - a genome-wide study of Japanese HCV virus patients. Gastroenterology 139(4), 1190-1197 (2010).
47. McCarthy MI, Abecasis GR, Cardon LR et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat. Rev. Genet. 9(5), 356-369 (2008). (Pubitemid 351556063)
48. Thursz M, Yee L, Khakoo S. Understanding the host genetics of chronic hepatitis B and C. Semin. Liver Dis. 31(2), 115-127 (2011).
49. Liaw YF, Lee CS, Tsai SL et al. T-cellmediated autologous hepatocytotoxicity in patients with chronic hepatitis C virus infection. Hepatology 22(5), 1368-1373 (1995).
50. Alric L, Fort M, Izopet J et al. Genes of the major histocompatibility complex Class II influence the outcome of hepatitis C virus infection. Gastroenterology 113(5), 1675-1681 (1997). (Pubitemid 27461256)
51. The MHC sequencing consortium. Complete sequence and gene map of a human major histocompatibility complex. . Nature 401(6756), 921-923 (1999).
52. Bieber T. Atopic dermatitis. N. Engl. J. Med. 358(14), 1483-1494 (2008).
53. Koziel MJ. Cellular immune responses against hepatitis C virus. Clin. Infect. Dis. 41(Suppl. 1), S25-S31 (2005). (Pubitemid 40863721)
54. Ishii S, Koziel MJ. Immune responses during acute and chronic infection with hepatitis C virus. Clin. Immunol. 128(2), 133-147 (2008).
55. Thursz M, Yallop R, Goldin R, Trepo C, Thomas HC. Influence of MHC Class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet 354(9196), 2119-2124 (1999).
56. Cramp ME, Carucci P, Underhill J, Naoumov NV, Williams R, Donaldson PT. Association between HLA Class II genotype and spontaneous clearance of hepatitis C viraemia. J. Hepatol. 29(2), 207-213 (1998). (Pubitemid 28352805)
57. Zavaglia C, Martinetti M, Silini E et al. Association between HLA Class II alleles and protection from or susceptibility to chronic hepatitis C. J. Hepatol. 28(1), 1-7 (1998). (Pubitemid 28122493)
58. Mangia A, Gentile R, Cascavilla I et al. HLA Class II favors clearance of HCV infection and progression of the chronic liver damage. J. Hepatol. 30(6), 984-989 (1999). (Pubitemid 29278740)
59. Yenigün A, Durupinar B. Decreased frequency of the HLA-DRB1*11 allele in patients with chronic hepatitis C virus infection. J. Virol. 76(4), 1787-1789 (2002). (Pubitemid 34094626)
60. Yu ML, Dai CY, Chen SC et al. Human leukocyte antigen Class I and II alleles and response to interferon-α treatment, in Taiwanese patients with chronic hepatitis C virus infection. J. Infect. Dis. 188(1), 62-65 (2003).
61. McKiernan SM, Hagan R, Curry M et al. Distinct MHC Class I and II alleles are associated with hepatitis C viral clearance, originating from a single source. Hepatology 40(1), 108-114 (2004). (Pubitemid 38877575)
62. Thio CL, Gao X, Goedert JJ et al. HLA-Cw*04 and hepatitis C virus persistence. J. Virol. 76(10), 4792-4797 (2002).
63. Kim AY, Kuntzen T, Timm J et al. Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes. Gastroenterology 140(2), 686.e1-696.e1 (2011).
64. Neumann-Haefelin C, Timm J, Schmidt J et al. Protective effect of human leukocyte antigen B27 in hepatitis C virus infection requires the presence of a genotype-specific immunodominant CD8+ T-cell epitope. Hepatology 51(1), 54-62 (2010).
65. Orange JS, Fassett MS, Koopman LA, Boyson JE, Strominger JL. Viral evasion of natural killer cells. Nat. Immunol. 3(11), 1006-1012 (2002). (Pubitemid 35363650)
66. Cheent K, Khakoo SI. Natural killer cells and hepatitis C: action and reaction. Gut 60(2), 268-278 (2011).
67. Khakoo SI, Thio CL, Martin MP et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305(5685), 872-874 (2004). (Pubitemid 39038423)
68. Knapp S, Warshow U, Hegazy D et al. Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus. Hepatology 51(4), 1168-1175 (2010).
69. Romero V, Azocar J, Zúñiga J et al. Interaction of NK inhibitory receptor genes with HLA-C and MHC Class II alleles in Hepatitis C virus infection outcome. Mol. Immunol. 45(9), 2429-2436 (2008).
70. Knapp S, Warshow U, Ho KM et al. A polymorphism in IL28B distinguishes exposed, uninfected individuals from spontaneous resolvers of HCV infection. Gastroenterology 141(1), 320-325, 325.e1 (2011).
71. Dai CY, Chuang WL, Chang WY et al. Tumor necrosis factor- α promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infection. J. Infect. Dis. 193(1), 98-101 (2006).
72. Huang Y, Yang H, Borg BB et al. A functional SNP of interferon-γ gene is important for interferon-α-induced and spontaneous recovery from hepatitis C virus infection. Proc. Natl Acad. Sci. USA 104(3), 985-990 (2007). (Pubitemid 46154723)
73. Mosbruger TL, Duggal P, Goedert JJ et al. Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virus. J. Infect. Dis. 201(9), 1371-1380 (2010).
74. Barrett S, Collins M, Kenny C, Ryan E, Keane CO, Crowe J. Polymorphisms in tumour necrosis factor-α, transforming growth factor-β, interleukin-10, interleukin-6, interferon-γ, and outcome of hepatitis C virus infection. J. Med. Virol. 71(2), 212-218 (2003). (Pubitemid 37048464)
75. Yu ML, Dai CY, Chiu CC et al. Tumor necrosis factor α promoter polymorphisms at position -308 in Taiwanese chronic hepatitis C patients treated with interferon-α. Antiviral Res. 59(1), 35-40 (2003).
76. McHutchison JG, Lawitz EJ, Shiffman ML et al.; IDEAL Study Team. Peginterferon α-2b or α-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 361(6), 580-593 (2009).
77. Tillmann HL, Thompson AJ, Patel K et al.; German Anti-D Study Group. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 139(5), 1586-1592, 1592. e1 (2010).
78. Grebely J, Petoumenos K, Hellard M et al.; ATAHC Study Group. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology 52(4), 1216-1224 (2010).
79. Thompson AJ, Fellay J, Patel K et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology 139(4), 1181-1189 (2010).
80. Conjeevaram HS, Fried MW, Jeffers LJ et al.; Virahep-C Study Group. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 131(2), 470-477 (2006). (Pubitemid 44142464)
81. Langhans B, Kupfer B, Braunschweiger I et al. Interferon-λ serum levels in hepatitis C. J. Hepatol. 54(5), 859-865 (2011).
82. Tseng TC, Yu ML, Liu CJ et al. Effect of host and viral factors on hepatitis B e antigenpositive chronic hepatitis B patients receiving pegylated interferon-a-2a therapy. Antivir. Ther. (Lond.) 16(5), 629-637 (2011).
83. Thompson AJ, Muir AJ, Sulkowski MS et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 139(1), 120.e18-129.e18 (2010).
84. Mangia A, Thompson AJ, Santoro R et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 139(3), 821-827, 827.e1 (2010).
85. Yu ML, Huang CF, Huang JF et al. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 53(1), 7-13 (2011).
86. Moghaddam A, Melum E, Reinton N et al. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology 53(3), 746-754 (2011).
87. Sarrazin C, Susser S, Doehring A et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J. Hepatol. 54(3), 415-421 (2011).
88. Rauch A, Kutalik Z, Descombes P et al.; Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138(4), 1338-1345, 1345.e1 (2010).
89. Rallón NI, Naggie S, Benito JM et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 24(8), F23-F29 (2010).
90. Fukuhara T, Taketomi A, Motomura T et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 139(5), 1577-1585, 1585.e1 (2010).
91. Charlton MR, Thompson A, Veldt BJ et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 53(1), 317-324 (2011).
92. Jacobson IM, McHutchison JG, Dusheiko G et al.; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364(25), 2405-2416 (2011).
93. McHutchison JG, Manns MP, Muir AJ et al.; PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med. 362(14), 1292-1303 (2010).
94. Bacon BR, Gordon SC, Lawitz E et al.; HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 364(13), 1207-1217 (2011).
95. Poordad F, McCone J Jr, Bacon BR et al.; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364(13), 1195-1206 (2011).
96. Hsu CS, Kao JH. Boceprevir for chronic HCV genotype 1 infection. N. Engl. J. Med. 365(2), 176-177; author reply 177 (2011).
97. Akuta N, Suzuki F, Hirakawa M et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 52(2), 421-429 (2010).
98. Manns MP, Gane E, Rodriguez-Torres M et al.; for the MK-7009 Protocol 007 Study Group. Vaniprevir with peginterferon α-2a and ribavirin in treatment-naive patients with chronic hepatitis C - a randomized Phase 2 study. Hepatology doi: 10.1002/hep.25743 (2012) (Epub ahead of print).
99. Kelly C, Klenerman P, Barnes E. Interferon λs: the next cytokine storm. Gut 60(9), 1284-1293 (2011).
100. Muir AJ, Shiffman ML, Zaman A et al. Phase 1b study of pegylated interferon λ 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 52(3), 822-832 (2010).
101. Marcello T, Grakoui A, Barba-Spaeth G et al. Interferons α and λ inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131(6), 1887-1898 (2006). (Pubitemid 44958521)